Quantcast
Last updated on April 23, 2014 at 16:13 EDT

Latest BioSpecifics Technologies Corp. Stories

2013-11-05 08:35:25

LYNBROOK, N.Y., Nov. 5, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®)( )in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Tuesday, November 12, 2013 to report its third quarter 2013 financial results and provide a corporate update....

2013-10-23 12:28:57

- First patient dosed in Phase 2a randomized, double-blind multiple-dose study - LYNBROOK, N.Y., Oct. 23, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has dosed the first patient in its Phase 2a study of XIAFLEX ("collagenase clostridium...

2013-10-07 16:25:31

- Clinical Papers Presented on Four-Year Data from CORDLESS Recurrence Study and Three-Year Safety Data - LYNBROOK, N.Y., Oct. 7, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced today that data from multiple trials evaluating the use of XIAFLEX ("collagenase clostridium histolyticum" or "CCH") in adult patients...

2013-09-19 16:26:25

LYNBROOK, N.Y., Sept. 19, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX(®) in the U.S and XIAPEX(®) in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Aegis Capital 2013 Healthcare Conference. The presentation will take place on Thursday, September 26, 2013 at 4:00 p.m. EDT (1:00 p.m. PDT) at the...

2013-09-04 08:32:06

LYNBROOK, N.Y., Sept. 4, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX(®) in the U.S and XIAPEX(®) in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Stifel Nicolaus 2013 Healthcare Conference at 9:10 a.m. EDT on Wednesday, September 11, 2013 in Boston, MA. The live webcast of this presentation can be...

2013-08-08 08:29:40

LYNBROOK, N.Y., Aug. 8, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX(® )in the U.S. and XIAPEX(®)( )in the EU, today reported its financial results for the second quarter ended June 30, 2013 and provided a corporate update. "We continue to make steady progress in the clinical development and commercial growth of XIAFLEX. We are anticipating a major landmark related...

2013-08-01 08:35:15

LYNBROOK, N.Y., Aug. 1, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®)( )in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, August 8, 2013 to report its second quarter 2013 financial results and provide a corporate update. In order to participate in the conference...

2013-07-23 08:31:30

LYNBROOK, N.Y., July 23, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum; CCH) in the U.S., announces that a poster titled, "Biomechanical Evaluation of Human Uterine Fibroids after Exposure to Purified Clostridial Collagenase" was presented today at the Society for the Study of Reproduction 46(th) Annual Meeting taking...

2013-07-16 20:21:37

LYNBROOK, N.Y., July 16, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has entered into a collaboration with Swedish Orphan Biovitrum AB (Sobi) for the long-term development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of...

2013-07-02 08:26:12

LYNBROOK, N.Y., July 2, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S., today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the 8(th) Annual JMP Securities Healthcare Conference at 4:00 p.m. EDT on Wednesday, July 10, 2013 in New York, NY. The live webcast of this presentation can be accessed under...